<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156427">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01952392</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CFR-BRI-2012/1</org_study_id>
    <nct_id>NCT01952392</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome</brief_title>
  <acronym>AReMIS</acronym>
  <official_title>Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>'CNIL': French Data Protection Authority, France.</authority>
    <authority>'HAS TC': Transparency Commission of the Haute Autorité de Santé (French National Authority for Health), France.</authority>
    <authority>'CEPS': Committee for Pricing of Healthcare Products, France.</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk
      of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a
      history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using
      ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where
      aspirin is considered a covariate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Medical information</measure>
    <time_frame>At baseline visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Current</time_frame>
    <safety_issue>No</safety_issue>
    <description>Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Recent</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug exposure</measure>
    <time_frame>Past</time_frame>
    <safety_issue>No</safety_issue>
    <description>Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other medical events of interest</measure>
    <time_frame>During follow-up (up to 12 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>rMI, stroke, bleeding, death</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3750</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <description>Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 years or more, both genders,with an acute coronary syndrome, agreed to
        participate and able to respond to an interview in French and/or providing the details of
        an alternative replier (proxy) if necessary.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS),
        agreed to participate and able to respond to an interview in French and/or providing the
        details of an alternative replier (proxy) if necessary.

        No Exclusion Criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence Thomas</last_name>
    <phone>+33141294025</phone>
    <email>ClinicalTrialTransparency@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>August 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectiveness study</keyword>
  <keyword>Acute coronary Syndrome</keyword>
  <keyword>Real-life</keyword>
  <keyword>France</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
